GMP-Creative Biolabs provides one-stop customer-oriented services including biopharmaceutical contract R&D, process development, cGMP manufacturing, QA & QC solutions for scientific research, preclinical, clinical and commercial supply. We proceed your projects according to your specific demands in quality, timeline and budget, supporting researchers across different therapeutic areas. Clear, open and regular communication with customers is as important to our success as our in-depth scientific knowledge. more
As a burgeoning biotech company in the GMP field, Creative Biolabs utilizes unparalleled techniques and platforms to provide stable cell line development services of various cells including SP2/0. In the very beginning of large-scale antibody expression, SP2/0 has been used with expression vectors, for instance pSV2, to generate recombinant stable cell lines.
There are various mammalian cell lines that have the machinery to produce recombinant proteins, among which only a limited number meet the fermentation requirements used in industrial manufacturing. As a major class of host cells, murine myeloma cells are widely used to generate a large number of monoclonal antibodies, with NS0 and SP2/0 being the most popular.
The usage of murine myeloma cells dates back to 1990s. NS0 and Sp2/0 have been used to manufacture about 15 mAbs and FcFP (Fc fusion proteins), a similar number as currently manufactured in CHO cells. They are capable of producing high levels of immunoglobulin due to the origination from non-differentiated B cells. SP2/0 and FO are also standard murine myeloma cell lines used as fusion partners to generate hybridomas. And FO is also derived from SP2/0.
SP2/0 is also known as Sp2/0-Ag-14 and it is derived from P3-X63-Ag-8 (X63). It was obtained by subcloning an X63 hybridoma, Sp2/3-3. NS-1-Ag4-1 (NS-1) and X63-Ag8.653 (X63.653) are also derived from the same original myeloma parent line but subcloned in several steps from X63. SP2/0 has been intensely used in mAb production. There are about 25% of mAbs marked in the US or EU that are produced in SP2/0 recombinant cells. Basiliximab, Canakinumab, Cetuximab, Infliximab, Abciximab, Golimumab, Ustekinumab, Eculizumab and Nimotuzumab are representatives and the first five have been approved by FDA and/or EMA.
Based on the target protein and special requirements of every client, Creative Biolabs can always be a perfect partner and provide the most appropriate strategy.
Creative Biolabs is capable of providing the following stable cell lines for various proteins expression:
To discuss your SP2/0 Cell Lines demands or to request a proposal, please contact us by
For R&D use only, not directly for clinical use.